# PT-141 FAQ: Bremelanotide Questions, Answered and Cited | PT-141 Score

> PT-141 FAQ: what it is, how it works, the approved use, the 1.75 mg dose, the half-life, and the receptors — direct, cited answers about bremelanotide.

Direct answers to the questions readers actually ask about PT-141 — definition, mechanism, the approved use, dose, and duration — each cited where it makes a quantitative claim.

## What is PT-141?

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide that acts as a melanocortin (MC3R/MC4R) receptor agonist [1]. It is FDA-approved (2019) as bremelanotide injection for acquired, generalized HSDD in premenopausal women, and not for any other use [3][6].

## What is PT-141 peptide?

A synthetic analogue of the natural hormone alpha-MSH: a cyclic seven-amino-acid peptide whose ring structure, closed by a lactam bridge, improves stability over linear melanocortin peptides [1]. Its molecular weight is 1025.2 Da. "PT-141 peptide" and "bremelanotide" name the same molecule [6].

## What does the PT-141 peptide do?

It activates central melanocortin receptors, chiefly MC4R, in hypothalamic and limbic circuits linked to sexual motivation, increasing sexual desire in the approved population rather than acting on blood flow [1][5]. An fMRI study showed it alters how the brain processes erotic stimuli [5].

## What is PT-141 used for?

Its only FDA-approved use is acquired, generalized HSDD in premenopausal women [3][6]. Use in men, for erectile dysfunction, or in postmenopausal women is off-label and investigational only, supported by early-phase or disputed evidence rather than approval [7][1].

## Is PT-141 the same as bremelanotide?

Yes. PT-141 is the developmental research designation; bremelanotide is the international nonproprietary name (INN) for the same melanocortin receptor agonist approved for HSDD [6]. The two terms refer to one identical compound [3].

## What is bremelanotide?

Bremelanotide is the approved-drug name for PT-141: an MC3R/MC4R agonist administered as a 1.75 mg subcutaneous as-needed injection, approved in June 2019 (NDA 210557) for HSDD in premenopausal women [6][3].

## How does PT-141 work?

By stimulating MC4R in hypothalamic circuits such as the medial preoptic area, engaging dopaminergic pathways governing sexual desire [1]. fMRI work shows MC4R agonism alters how the brain processes erotic stimuli, confirming a central rather than vascular mechanism [5].

## What receptors does PT-141 act on?

Principally the melanocortin 4 receptor (MC4R), with the melanocortin 3 receptor (MC3R) as a secondary central target [1]. Peripheral MC1R activation underlies the hyperpigmentation seen with repeated dosing [6].

## Does PT-141 work through the brain or through blood flow?

Through the brain. Unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle, PT-141 works centrally on the neural circuitry of sexual motivation [5][1]. It is a signal-in-a-circuit drug, not a blood-flow drug.

## What is a melanocortin receptor agonist?

A molecule that activates one or more of the five melanocortin receptors (MC1R-MC5R) [1]. PT-141 activates the central MC3R/MC4R subtypes that respond to the endogenous peptide alpha-MSH, which is the receptor family it was designed to engage [1].

## Does PT-141 increase testosterone?

No. PT-141 does not act via the HPG axis and does not directly raise testosterone; it acts on central melanocortin receptors [1]. The idea that it works by boosting testosterone is a common misconception about the mechanism.

## How is PT-141 different from PDE-5 inhibitors?

PDE-5 inhibitors (such as sildenafil) act peripherally on vascular smooth muscle to improve erectile blood flow [5]. PT-141 acts centrally on MC4R circuits governing sexual desire — a fundamentally different mechanism aimed at motivation, not hemodynamics [1].

## What is the PT-141 dosage?

As a finding only: the approved label specifies 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated activity, no more than one dose per 24 hours and no more than 8 per month [6]. This is not a protocol for any reader.

## How much PT-141 should I take?

This site recommends no dose for any individual. The trial and label dose in premenopausal women with HSDD was 1.75 mg subcutaneous as-needed — a reported study finding, not guidance [6][3].

## How much PT-141 to inject?

The approved subcutaneous dose studied was 1.75 mg per administration [6]. Phase 2 dose-finding evaluated 0.75, 1.25, and 1.75 mg [6]. Reported as findings, not as a self-administration instruction.

## What is the PT-141 dosage for women?

In premenopausal women with HSDD, the approved label dose is 1.75 mg subcutaneous as-needed, with a maximum of one dose per 24 hours and 8 per month [6]. Reported here as the studied and labeled regimen only.

## How do you reconstitute PT-141?

The approved finished product is a pre-formulated single-dose subcutaneous injection, not a reconstituted powder [6]. Material sold as "PT-141 research chemical" is for laboratory research only and is not the approved drug [3].

## How do you take PT-141?

In the trials and label, bremelanotide is self-administered as a subcutaneous injection at least 45 minutes before anticipated activity [6]. Described here as the studied route, not as instructions to follow.

## How often can you take PT-141?

The label limits dosing to no more than one 1.75 mg dose per 24 hours and no more than 8 doses per month [6]. Reported as the labeled limit, not as a recommendation.

## What is the approved bremelanotide dose?

1.75 mg subcutaneous, as needed, with a maximum of one dose per 24 hours and 8 doses per month, per the US prescribing information [6]. This is the labeled regimen for the approved HSDD indication.

## How long does PT-141 last?

The terminal half-life is approximately 2.7 hours (range 1.9-4.0 h) after subcutaneous administration per the US label, with median Tmax about 0.5-1.0 hour [6]. Desire effects were recorded for up to 24 hours in the fMRI study [5].

---

PT-141 Score reads the bremelanotide record like a program — the one approved use and the nausea-led tolerability cost set loud and first, the modest effect drawn honestly small beside the re-analyses that contest it, and the unverified field reports kept off-stave in their own key; no clinic behind the score and nothing here dosed, prescribed, or sold.